□□□

□□

- □□
- □□□□□□
- □□□□□□□□□□□□□
- □□□□□
- □□□□□□□□□□□□
- □□□□□
- □□□□□□□□□
- □□□□□□□□□□
- □□□□□□□□□□□□
- □□□□□


□□

□□□□□□□□□□□□

□□□

□□CGRPs□□mRNAs□□□□□□(Amara et al., 1982)□


□□□□□□□□□□□□□□□□□□□




4A-(cat. no. 403 004, 1:500,)PFADAPI

4B- (cat. no. 408 004, 1:500,)PFADAPI

(Hökfelt et al., 2003)CGRP5A5B(Edvinsson et al., 2018, Russo, 2015)







5A-(cat. no. 459 005, 1:500,)PFADAPI

5B-(cat. no. 414 004, 1:1000, DAB)PFA

Y6A6BIHC
(Hökfelt et al., 2003)





6A-Y (cat. no. 394 006, 1:500,)PFADAPI(10mM Tris, 1mM EDTA, pH 9.0, 60°C)

6B-(cat. no. 446 004, 1 : 1000, DAB)PFA

ACTH	(Gallo-Payet, 2016)
AGRP	(Ilnytska and Argyropoulos, 2008)
CART	(Rogge et al., 2008)
CCK-8	(Lee and Soltesz, 2011)
CGRP	(Benarroch, 2011)
CRF	(Vitoratos et al., 2006)
Galanin	/(Lang et al., 2015)
Neuropeptide S	(Grund and Neumann, 2019)
Neuropeptide Y	(Reichmann and Holzer, 2016)
Neurotensin	(Saiyasit et al., 2018)

Orexin	□□□□□□□□□□□□□□□□□(Nixon et al., 2015)□
Oxytocin	□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□(Lee et al., 2009)□
Somatostatin	□□□□□□□□□□□□□□□□(Gehete et al., 2010)□
Substance P	□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□(Schank and Heilig, 2017)□
Vasopressin	□□□□□□□□□□□□□□□□□□(Caldwell et al., 2008)□
VIP	□□□(Iwasaki et al., 2019).


□□□□□□□□


□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□

□□□□□□□□□□□□□□□□□□□

□□□□□□□□□

□□□□□□□□





□8C□□□□□□□-8□□□□□□□□□(cat. no. 438 004,□□□□1:500,□□) □□□-MAP 2□□(cat. no. 188 002, □□□□1:1000, □□)□□PFA□□□□□□□□□□□□□□□□□□□□□□□□□□□DAPI□□□□□□□□

□8D□□□□□□□-□□□□□□□□□(cat. no. 443 005, □□□□1:100, □□)□□□-MAP 2 □□(cat. no. 188 002, □□□□1:1000, □□)□□□PFA□□□□□□□□□□□□□□□□□□□□□□□□□□□DAPI□□□□□□□□□

□□□□□□□□□□□

Cat. No.	Product Description	Application	Quantity	Price	Cart
452 005	ACTH, Guinea pig, affinity	IHC IHC-P (FFPE)	50 µg	US$465.00	
438 004	CCK-8, Guinea pig, antiserum	ICC IHC IHC-P (FFPE)	100 µl	US$375.00	
414 004	CGRP, Guinea pig, antiserum	ICC IHC IHC-P (FFPE) iDISCO Clarity	100 µl	US$370.00	
414 017	CGRP, rat, IgG K.O.	IHC IHC-P (FFPE)	100 µg	US$420.00	
259 002	Chromogranin A, rabbit, antiserum	WB	200 µl	US$360.00	
259 003	Chromogranin A, rabbit, affinity K.O.	WB ICC IHC IHC-P (FFPE)	50 µg	US$460.00	
259-0P	Chromogranin A, control protein		100 µg	US$110.00	
259 103	Chromogranin B, rabbit, affinity K.O.	WB ICC IHC IHC-P (FFPE) EM	50 µg	US$380.00	

259-1P	Chromogranin B, control protein		100 µg	US$110.00
529 004	CRF, Guinea pig, antiserum	ICC IHC	100 µl	US$370.00
446 004	Galanin, Guinea pig, antiserum	ICC IHC IHC-P (FFPE)	100 µl	US$370.00
468 003	Ghrelin, rabbit, affinity	IHC IHC-P (FFPE)	50 µg	US$380.00
514 003	GIP, rabbit, affinity	IHC IHC-P (FFPE)	50 µg	US$380.00
471 005	GLP-1, Guinea pig, affinity	Dot blot IHC IHC-P (FFPE)	50 µg	US$465.00
471 203	GLP-2, rabbit, affinity	Dot blot IHC IHC-P (FFPE)	50 µg	US$380.00

Result count: **32**

□□□Beate Friedrich□□

Beate□□□

Gahete et al., 2010: Somatostatin and its receptors from fish to mammals. PMID: 20633132

Gallo-Payet, 2016: 60 years of POMC: adrenal and extra-adrenal functions of ACTH. PMID: 26793988

Grund and Neumann, 2019: Brain neuropeptide S: via GPCR activation to a powerful neuromodulator of socio-emotional behaviors. PMID: 30112573

Hökfelt et al., 2003: Neuropeptides: opportunities for drug discovery. PMID: 12878434

Hook, 2008: Proteases for processing proneuropeptides into peptide neurotransmitters and hormones. PMID: 18184105

Ilnytska and Argyropoulos, 2008: The role of the Agouti-related protein in energy balance regulation. PMID: 18470724

Iwasaki et al., 2019: Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system. PMID: 31559013

Kastin, 2000: What is a neuropeptide? PMID: 10675912

Lang et al., 2015: Physiology, signaling, and pharmacology of galanin peptides and receptors: three decades of emerging diversity. PMID: 25428932

Lee and Soltesz, 2011: Cholecystokinin: a multi-functional molecular switch of neuronal circuits. PMID: 21154912

Lee et al., 2009: Oxytocin: the great facilitor of life. PMID: 19482229

Mains and Eipper, 1999: The Neuropeptides. Bookshelf ID: NBK28247 https://www.ncbi.nlm.nih.gov/books/NBK28247

Nixon et al., 2015: Sleep disorders, obesity, and aging: the role of orexin. PMID: 25462194

Rehfeld et al., 2008: The cell-specific pattern of cholecystokinin peptides in endocrine cells versus neurons is governed by the expression of prohormone convertases 1/3, 2, and 5/6. PMID: 18096669

Reichmann and Holzer, 2016: Neuropeptide Y: A stressful review. PMID: 26441327

Rogge et al., 2008: CART peptides : regulators of body weight, reward and other functions. PMID: 18802445

Russo, 2015: Calcitonin gene-related peptide (CGRP): A new target for migraine. PMID: 25340934

Russo, 2017: Overview of neuropeptides: Awakening the senses? PMID: 28485842

Saiyasit et al, 2018: Potential roles of neurotensin on cognition in conditions of obese-insulin resistance. PMID: 30279001

Schank and Heilig, 2017: Substance P and the Neurokinin-1 Receptor: The new CRF. PMID: 29056150

Sevivas and Fresco, 2022: Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review. PMID: 35659086

Sun and Zhao, 2017: Peptide hormones as tumor markers in clinical practice. PMID: 29054271

Van den Pol, 2012: Neuropeptide transmission in brain circuits. PMID: 23040809

Vandervorst et al., 2021: CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. PMID: 34696711

Vitoratos et al., 2006: “Reproductive” corticotropin-releasing hormone. PMID: 17308156